Clinical implications of portal hemodynamics after small-diameter portacaval H graft.
To assess the role of portal hemodynamics in the development of postshunt encephalopathy, we studied 19 patients after small-diameter portacaval H grafting (SD-PCHG). We used contrast studies as well as technetium-labeled macroaggregated albumin injected into the portal vein to assess direction of portal flow. We then quantitated the mesenteric fraction of flow perfusing the liver by injecting macroaggregated albumin into a peripheral mesenteric vein tributary. We found that none of seven patients with prograde flow by both scintigraphy and angiography developed postoperative encephalopathy, but the incidence was 58% in the remaining patients (p = 0.02). The fraction of mesenteric flow perfusing the liver after SD-PCHG was 12% +/- 4%, but this did not significantly correlate with encephalopathy rates. We conclude that after SD-PCHG, prograde portal flow minimizes encephalopathy rates. Although encephalopathy occurs in patients with predominantly reversed flow, a subgroup of patients with reversed flow remain without symptoms. The absolute fraction of mesenteric flow perfusing the liver has less influence on encephalopathy rates than has direction of portal flow. This study identifies a complex relationship between portal hemodynamics and encephalopathy.
D000792:Angiography; D006501:Hepatic Encephalopathy / Q000209:etiology; D006801:Humans; D007275:Injections, Intravenous; D008102:Liver Circulation; D008642:Mesenteric Veins; D011167:Portacaval Shunt, Surgical / Q000009:adverse effects / Q000379:methods*; D011168:Portal System / Q000502:physiology*; D011169:Portal Vein / Q000502:physiology; D011184:Postoperative Period; D011652:Pulmonary Circulation; D012039:Regional Blood Flow; D012709:Serum Albumin / Q000008:administration & dosage; D013667:Technetium / Q000008:administration & dosage; D013668:Technetium Tc 99m Aggregated Albumin
D012709:Serum Albumin; D013668:Technetium Tc 99m Aggregated Albumin; D013667:Technetium